TY - JOUR
T1 - Dyslipoproteinemia and diabetes
AU - Garg, A.
N1 - Funding Information:
This work was supported by grants HL-29252 and M01-RR00633 from the National Institutes of Health
PY - 1998
Y1 - 1998
N2 - Dyslipidemia in patients with diabetes constitutes quantitative and qualitative abnormalities in all classes of lipoproteins and may be a significant contributor to the high risk of atherosclerosis in these patients. A step-care approach to therapy of diabetic dyslipidemia, including hygienic measures (diet and increased physical activity), hypoglycemic drugs, and lipid-lowering drugs, is recommended. The choice of lipid-lowering drugs depends on severity of hypertriglyceridemia. Statins and bile-acid-binding resins are the choice of therapy for diabetic dyslipidemia; however, for severely hypertriglyceridemic patients, fibric acid derivatives should be used. Nicotinic acid worsens hyperglycemia and, therefore, should be avoided. The value of estrogen replacement therapy in postmenopausal women with diabetes has not been established.
AB - Dyslipidemia in patients with diabetes constitutes quantitative and qualitative abnormalities in all classes of lipoproteins and may be a significant contributor to the high risk of atherosclerosis in these patients. A step-care approach to therapy of diabetic dyslipidemia, including hygienic measures (diet and increased physical activity), hypoglycemic drugs, and lipid-lowering drugs, is recommended. The choice of lipid-lowering drugs depends on severity of hypertriglyceridemia. Statins and bile-acid-binding resins are the choice of therapy for diabetic dyslipidemia; however, for severely hypertriglyceridemic patients, fibric acid derivatives should be used. Nicotinic acid worsens hyperglycemia and, therefore, should be avoided. The value of estrogen replacement therapy in postmenopausal women with diabetes has not been established.
UR - http://www.scopus.com/inward/record.url?scp=0031719981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031719981&partnerID=8YFLogxK
U2 - 10.1016/S0889-8529(05)70029-3
DO - 10.1016/S0889-8529(05)70029-3
M3 - Article
C2 - 9785056
AN - SCOPUS:0031719981
SN - 0889-8529
VL - 27
SP - 613
EP - 625
JO - Endocrinology and Metabolism Clinics of North America
JF - Endocrinology and Metabolism Clinics of North America
IS - 3
ER -